Discontinuation report RANITIDINE INJECTION USP
Report ID | 127687 |
Drug Identification Number | 02256711 |
Brand name | RANITIDINE INJECTION USP |
Common or Proper name | RANITIDINE |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | RANITIDINE |
Strength(s) | 50MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS |
Packaging size | 1 VIAL 50ML |
ATC code | A02BA |
ATC description | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
Reason for discontinuation | Manufacturing issues |
Anticipated discontinuation date | |
Actual discontinuation date | 2020-11-02 |
Remaining supply date | 2020-11-02 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | PrFamotidine Omega 10mg/mL as a substitute for PrRanitidine Injection USP 25 mg/mL |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2020-11-03 | English | Compare |
v2 | 2020-11-02 | French | Compare |
v1 | 2020-11-02 | English | Compare |
Showing 1 to 3 of 3